<DOC>
	<DOCNO>NCT01598038</DOCNO>
	<brief_summary>The investigator hypothesize everolimus toxicity link pharmacokinetic variability everolimus . Thus , early detection clinical biological risk factor lead personalized dosage treatment permit good tolerance without alter efficacy .</brief_summary>
	<brief_title>Relation Between Safety Endpoints Everolimus Trough Blood Level Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients age â‰¥ 18 yearold . 2 . Histologically documented renal cell carcinoma whatever type . 3 . One two prior therapy cytokine and/or VEFGligand inhibitor permit . 4 . Patients indication receive everolimus treatment 5 . Patients able willing give write informed consent , first screen procedure . 1 . Patients currently receive chemotherapy immunotherapy 2 . Prior treatment temsirolimus 3 . Contraindication everolimus : Hypersensitivity active substance , rapamycin derivative excipients . Patients severe hepatic impairment ( ChildPugh class C ) Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption take medicinal product . 4 . Pregnant breastfeed woman 5 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>renal</keyword>
	<keyword>Afinitor</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>